Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

70.11EUR
8:41am EDT
Change (% chg)

€0.21 (+0.30%)
Prev Close
€69.90
Open
€69.68
Day's High
€70.25
Day's Low
€69.51
Volume
28,317
Avg. Vol
101,946
52-wk High
€72.00
52-wk Low
€42.68

Latest Key Developments (Source: Significant Developments)

Biomerieux H1 operating income rises to 163 million euros
Wednesday, 30 Aug 2017 01:18am EDT 

Aug 30 (Reuters) - BIOMERIEUX SA ::IS NOW TARGETING ORGANIC SALES GROWTH FOR FULL YEAR OF BETWEEN 9 PCT AND 10 PCT.EUR 1,134 MILLION IN SALES ‍​IN H1, UP 13.3 PCT AS REPORTED.IS NOW AIMING TO DELIVER FULL-YEAR CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS OF BETWEEN EUR 330 MILLION AND EUR 345 MILLION.IN H1 18 PCT INCREASE IN NET INCOME TO EUR 101 MILLION.2017 FINANCIAL TARGETS REVISED: ORGANIC GROWTH IN SALES OF BETWEEN 9 PCT AND 10 PCT ‍​.H1 OPERATING INCOME EUR 163 MILLION VERSUS EUR 146 MILLION YEAR AGO.  Full Article

Biomérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS
Monday, 31 Jul 2017 01:01am EDT 

July 31 (Reuters) - BIOMERIEUX SA : :BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR EXPANDED PATHOGEN IDENTIFICATION CAPABILITY ON VITEK® MS.  Full Article

Sysmex and Biomérieux agreed to dissolve JV Sysmex Biomérieux co., ltd.
Thursday, 27 Jul 2017 02:01am EDT 

July 27 (Reuters) - BIOMERIEUX SA : :SYSMEX AND BIOMÉRIEUX AGREED TO DISSOLVE THE JOINT VENTURE SYSMEX BIOMÉRIEUX CO., LTD..‍SYSMEX AND BIOMÉRIEUX HAVE AGREED TO TRANSFER ALL OF SYSMEX' HOLDINGS IN SYSMEX BIOMÉRIEUX TO BIOMÉRIEUX​.SYSMEX WILL TRANSFER ALL OF ITS HOLDINGS IN SYSMEX BIOMÉRIEUX (34% OF SHARES) TO BIOMÉRIEUX.‍DISTRIBUTION AGREEMENT RELATING TO DISTRIBUTION OF BIOMÉRIEUX PRODUCTS IN JAPAN BETWEEN SYSMEX AND SYSMEX BIOMÉRIEUX WILL ALSO TERMINATE AS OF OCTOBER 31, 2017​.‍SYSMEX WILL CONTINUE TO PROVIDE CUSTOMER SERVICE IN JAPAN FOR BIOMÉRIEUX PRODUCTS UNTIL MARCH 31, 2018​.‍SHARE TRANSFER DATE OCTOBER 31, 2017 (SCHEDULED)​.  Full Article

Biomerieux H1 sales up at 1,134 million euros
Thursday, 20 Jul 2017 01:10am EDT 

July 20 (Reuters) - BIOMERIEUX SA ::SALES UP 11.3% OVER FIRST HALF AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION​.H1 €1,134 MILLION IN SALES‍​.‍FOR 2017 CONFIDENT THAT IT WILL ACHIEVE HIGHER END OF ITS TARGET ORGANIC SALES GROWTH RANGE OF BETWEEN 8% AND 9%​.  Full Article

Biomerieux receives FDA clearance for BioFire’s FilmArray Respiratory Panel 2 (RP2)
Thursday, 1 Jun 2017 01:00am EDT 

June 1 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR BIOFIRE’S FILMARRAY RESPIRATORY PANEL 2 (RP2).BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR BIOFIRE'S FILMARRAY RESPIRATORY PANEL 2 (RP2).‍FILMARRA RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ENHANCING PATHOGEN COVERAGE AND OVERALL SENSITIVITY​.FILMARRAY RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ENHANCING PATHOGEN COVERAGE AND OVERALL SENSITIVITY.‍FOLLOWS ANNOUNCEMENT IN APRIL THAT FILMARRAY(®) RESPIRATORY PANEL 2 PLUS (RP2PLUS) IS CE MARKED​.  Full Article

Biomerieux Q1 Consolidated sales rise to 568 million euros
Thursday, 20 Apr 2017 01:24am EDT 

April 20 (Reuters) - Biomerieux SA ::Consolidated sales rose to 568 million euros ($609.18 million) for the first three months of 2017, up from 489 million euros in the same period one year earlier.  Full Article

Biomerieux receives FDA 510(k) clearance for BacT/ALERT VIRTUO fully automated blood culture system
Thursday, 6 Apr 2017 01:00am EDT 

Biomerieux Sa :Biomerieux receives FDA 510(k) clearance for its BacT/ALERT VIRTUO fully automated blood culture system.  Full Article

Biomerieux FY sales up 7.1 pct as reported at 2.10 billion euros
Wednesday, 1 Mar 2017 01:09am EST 

Biomerieux Sa : Board of directors will recommend that shareholders at annual meeting on May 30 approve a dividend of 1.00 euros per share . FY sales 2.10 billion euros ($2.22 billion) versus 1.97 billion euros year ago . 2017 objectives: . organic growth in sales of between 8 pct and 9 pct . Dividend is unchanged from dividend paid previous year . FY earnings per share 4.54 euros versus 2.80 euros year ago . Dividend would represent a total payout of 39.5 million euros, to be paid on June 8, 2017. . 2017 objectives: contributive operating income before non-recurring items of between 300 million euros and 315 million euros .FY operating income 282 million euros versus 195 million euros year ago.  Full Article

Biomerieux launches first FDA-cleared procalcitonin assay
Friday, 24 Feb 2017 01:00am EST 

Biomerieux SA :Biomérieux’s VIDAS BRAHMS PCT becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis.  Full Article

FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis
Thursday, 23 Feb 2017 05:41pm EST 

Biomerieux Sa : U.S. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis . U.S. FDA - cleared expanded use of Vidas Brahms percent assay to help manage antibiotic treatment for lower respiratory tract infections and sepsis .U.S. FDA - Vidas Brahms test is manufactured by Biomérieux Inc.  Full Article

Photo

European stocks bounce back as strong earnings in focus

LONDON Investors piled back into European stocks on Wednesday, boosting indexes higher in a rally a day after geopolitical concern caused a drop across equity markets.